Search

Royalty Pharma PLC (Class A)

Slēgts

SektorsVeselības aprūpe

58.44 -0.9

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

57.74

Max

59.03

Galvenie mērījumi

By Trading Economics

Ienākumi

-589M

-295M

Pārdošana

44M

674M

P/E

Sektora vidējais

31.747

56.432

EPS

1.32

Dividenžu ienesīgums

1.55

Peļņas marža

-43.713

Darbinieki

100

EBITDA

-387M

176M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+11.29% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

1.55%

2.27%

Nākamie ieņēmumi

2026. g. 4. nov.

Nākamais dividenžu datums

2026. g. 9. dec.

Nākamais Ex dividenžu datums

2026. g. 13. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.2B

34B

Iepriekšējā atvēršanas cena

59.34

Iepriekšējā slēgšanas cena

58.44

Ziņu noskaņojums

By Acuity

15%

85%

17 / 339 Rangs Healthcare

Royalty Pharma PLC (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. sept. 23:16 UTC

News

Royalty Pharma announced a $7.5 million donation to Blood Cancer United. Shares are lower in after-market trading amid rising Treasury yields.

2026. g. 14. sept. 20:07 UTC

Royalty Pharma PLC shares are higher today, reflecting a modest gain since Friday. Broader market concerns over rising crude oil prices may be influencing sentiment.

2026. g. 11. sept. 20:08 UTC

Royalty Pharma PLC shares are lower today, pulling back from earlier gains amid broader market dynamics and inflation pressures influencing Federal Reserve policy.

2026. g. 10. sept. 23:46 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing a rise since Thursday's close, though still below the 20-day moving average.

2026. g. 9. sept. 20:07 UTC

News

Royalty Pharma shares lower today, following a decline after Novartis' trial failure. Analysts suggest the drop may be overdone amid stable royalty expectations.

2026. g. 8. sept. 21:01 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting broader market dynamics despite no specific company news identified.

2026. g. 5. sept. 00:01 UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

2026. g. 4. sept. 22:14 UTC

Royalty Pharma PLC shares are trading lower during after-market hours, breaking a trend of higher daily closes. No specific news was identified for the decline.

2026. g. 3. sept. 23:05 UTC

Royalty Pharma PLC shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2026. g. 2. sept. 23:06 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting a slight decline since Wednesday's close, despite earlier recovery attempts.

2026. g. 1. sept. 20:09 UTC

Royalty Pharma PLC is rising as strength in the pharmaceuticals sub-sector boosts shares. The stock remains near its one-month high despite a recent pullback.

2026. g. 31. aug. 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting positive market sentiment. The stock remains near the upper end of its one-month trading range.

2026. g. 28. aug. 20:07 UTC

Royalty Pharma PLC shares are lower today amid broader market declines and rising U.S. Treasury yields, reflecting ongoing volatility in the pharmaceuticals sector.

2026. g. 27. aug. 23:11 UTC

Royalty Pharma PLC shares are higher in after-market trading, supported by a favorable performance backdrop and positioning above the 20-day moving average.

2026. g. 26. aug. 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, currently above their 20-day moving average and near the upper end of their one-month range.

2026. g. 25. aug. 20:07 UTC

Royalty Pharma PLC shares are higher today, continuing an upward trend since Monday. Lower Treasury yields are supporting investor sentiment in the market.

2026. g. 24. aug. 20:06 UTC

Royalty Pharma PLC shares are near unchanged as market sentiment is influenced by rising oil prices and geopolitical tensions from new U.S. sanctions against Iran.

2026. g. 21. aug. 19:26 UTC

Royalty Pharma PLC shares are higher, reflecting a broader rebound in U.S. stocks amid economic uncertainties and rising inflation. The asset remains above its 20-day moving average.

2026. g. 20. aug. 23:11 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline from earlier in the session amid mixed broader market sentiment.

2026. g. 19. aug. 20:02 UTC

Royalty Pharma PLC shares are higher today, driven by strong investor interest in pharmaceuticals and unusually high market volume during regular trading hours.

2026. g. 18. aug. 23:21 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing an upward trend from previous sessions. No specific news was identified for this movement.

2026. g. 17. aug. 19:36 UTC

Royalty Pharma PLC shares are trading higher during Monday's session, recovering from an earlier dip and remaining above the 20-day moving average.

2026. g. 15. aug. 00:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a routine decline since Friday's close amid mixed global equity market performance.

2026. g. 14. aug. 19:46 UTC

Event
Social Media

Royalty Pharma PLC declared a $0.235 per share dividend today, with shares advancing since Thursday's close and near the upper end of their one-month range.

2026. g. 13. aug. 20:02 UTC

Social Media

Royalty Pharma PLC shares are lower amid a $100 million royalty agreement with Zealand Pharma for rusfertide rights, reflecting unusual trading activity.

2026. g. 12. aug. 20:01 UTC

Royalty Pharma PLC shares are higher today, supported by a broader market trend of gains since Tuesday. The stock is seeing unusually high trading volume.

2026. g. 11. aug. 19:56 UTC

Royalty Pharma PLC shares are trading higher, reaching a session high earlier today. No specific news was identified to explain the price movement.

2026. g. 10. aug. 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting notable strength and unusual activity since Monday's close, with no specific news identified.

2026. g. 7. aug. 23:41 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting notable gains since Friday's close amid a shift toward a dovish monetary policy outlook.

2026. g. 6. aug. 23:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Royalty Pharma PLC (Class A) Prognoze

Cenas mērķis

By TipRanks

11.29% augšup

Prognoze 12 mēnešiem

Vidējais 65.714 USD  11.29%

Augstākais 70 USD

Zemākais 62 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Royalty Pharma PLC (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

7

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

17 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat